When Genomics Moves at the Speed of Medicine

Article

Whole-genome sequencing (WGS) is steadily moving from a specialized tool for difficult genetic cases toward a broader role in clinical medicine. A recent study in Nature Medicine provides a useful example of what becomes possible when genomic information can be delivered quickly enough to influence care. Researchers implemented rapid whole-genome sequencing across neonatal and pediatric intensive care units in Dubai, studying 100 critically ill children suspected of having genetic disease. The difference compared with historical genetic testing was substantial. Median turnaround time fell from 38 days to 3.4 days, while the molecular diagnostic yield increased from approximately 30% to 53%. More importantly, the genomic findings resulted in a clinically meaningful change in management in 53% of patients. Those changes included medications, dietary interventions, procedures, additional testing, specialist referrals and, in some cases, decisions about goals of care. The study is focused on critically ill children, but it illustrates a much larger opportunity for WGS. Where WGS Could Be Useful Rare and undiagnosed disease is already one of the clearest applications. Instead of moving sequentially through individual genes and panels, WGS can provide a broad search for an underlying genetic cause, particularly when the clinical picture does not point toward a single disorder. Critical care adds the element of time. Rapid WGS may help identify metabolic disorders, epileptic encephalopathies, immune deficiencies, cardiomyopathies and other genetic conditions while treatment decisions are still being made. Cancer represents another important opportunity. WGS can provide a broad picture of the tumor genome, including mutations, copy-number changes and structural rearrangements. Tumor-normal sequencing can also help distinguish acquired tumor alterations from inherited variants. Whether WGS ultimately replaces today's targeted oncology panels will depend on clinical utility, turnaround time, cost and regulatory considerations. Inherited cancer and cardiovascular disease provide a different use case. Pathogenic germline variants can identify individuals and families at increased risk for conditions such as hereditary breast and ovarian cancer, Lynch syndrome, familial hypercholesterolemia, cardiomyopathies and inherited arrhythmias. Finding these variants can lead to surveillance, prevention and testing of relatives before disease presents clinically. Pharmacogenomics offers an intriguing longer-term application. Genetic variants can influence drug metabolism, toxicity and response. Rather than ordering a new genetic test each time a medication question arises, genomic information obtained once could potentially be queried repeatedly as clinically validated pharmacogenomic relationships expand. Reproductive and prenatal medicine may also benefit, particularly when fetal abnormalities or family histories suggest a genetic disorder that cannot be explained by conventional testing. There is even growing interest in population screening, where sequencing could identify actionable genetic risks before symptoms develop. That possibility is compelling, but it also raises difficult questions about penetrance, incidental findings, cost, access and which genomic findings actually improve outcomes when returned to otherwise healthy people. And genomic sequencing is not limited to sequencing the patient. In infectious disease and public health, whole-genome sequencing of pathogens can help characterize organisms, identify resistance mechanisms, investigate transmission and track outbreaks. The Genome as a Reusable Clinical Resource Perhaps the most interesting long-term implication of WGS is that a genome does not necessarily represent a one-time diagnostic test. A patient's genomic sequence could potentially become a longitudinal clinical resource. A genome sequenced today because of an unexplained disease might later be reanalyzed for an inherited cancer syndrome, a cardiovascular risk variant or a pharmacogenomic question. As new gene-disease relationships and therapies are discovered, existing genomic data can potentially be interpreted again without sequencing the patient again. This suggests a different model for genomic medicine:sequence once, interrogate many times. There are important limitations. WGS does not detect every type of genetic abnormality equally well, and identifying a variant does not necessarily mean that it causes disease or provides an actionable treatment. Interpretation, data storage, privacy, cost, equitable access and integration into clinical workflow remain significant challenges. That is why the Dubai study is important. It doesn't establish that everyone should undergo whole-genome sequencing. It demonstrates something more fundamental: when genomic information can be generated, interpreted and returned within the clinical decision window, sequencing can move from explaining disease to changing care. The next challenge for genomic medicine is therefore not simply sequencing more genomes. It is determiningwhich information matters, for which patient, at what point in their care—and getting that information to the clinician in time to act on it. Reference:Rabea F, Aljasmi I, Jain R, et al.Citywide implementation of a rapid whole-genome sequencing program for critically ill pediatric patients.Nature Medicine. 2026.